Altimmune Inc ALT 深 滬
已收盤 08-07 16:00:00 美东时间
3.08
+0.070
+2.33%
華盛通- 最 高3.10
- 今 開3.05
- 成交量 450.59万股
- 最 低 3.00
- 昨 收 3.01
- 總市值 5.99亿
- 52周最高 6.4399
- 市盈率 靜 --
- 換手率 2.32%
- 52周最低 2.56
- 委 比 -47.32%
- 總股本 1.94亿
- 歷史最高 237.30
- 量 比 0.94
- 振 幅 3.32%
- 歷史最低 1.51
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company developing pemvidutide for serious liver diseases, announced it will report its second quarter 2026 financial results on August 12, 2026. A conference call will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call will be webcast live on Altimmune’s Investor Relations website, with registration available for dial-in details. A replay will ...
08-05 12:00
Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which a...
07-28 19:05
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Altimmune's pemvidutide demonstrated statistically significant reductions in heavy drinking days (HDD) and achieved key secondary endpoints in the Phase 2 RECLAIM trial for moderate to severe alcohol use disorder (AUD). The trial showed a 2-level reduction in WHO risk drinking levels, zero HDD, and significant improvements in abstinence and PEth biomarker levels. Pemvidutide was generally well-tolerated, with a favorable safety profile. The compa...
07-28 11:00
Zacks行业展望：Indivior、Aurinia、Ironwood、Altimmune及Marker
2026年6月26日，扎克斯股票研究聚焦5只小型制药标的：Indivior制药（INDV）、Aurinia制药（AUPH）、Ironwood制药（IRWD）、...
06-26 18:07
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10
Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperform rating and announces Price Target of $10.
06-22 22:41
Altimmune Relocates Corporate Headquarters to Morristown, New Jersey
The latest announcement is out from Altimmune ( ($ALT) ). On June 16, 2026, Alt...
06-17 04:47
GLP-1 sales forecast increased to $150B at TD Cowen
GLP-1 drugs, the treatment class popularized by Eli Lilly (LLY) and Novo Nordisk (NVO), could generate $150B in global sales by the end of this decade, TD Cowen estimates, indicating a roughly ~8% inc...
06-05 22:22
Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis.
The data are being presented today and Friday in poster sessions, including a late-breaking poster presentation, at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain.
05-27 20:03
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Altimmune, Inc. announced that new analyses from the IMPACT Phase 2b trial show pemvidutide, a dual receptor agonist, significantly improves multiple non-invasive tests (NITs) for MASH activity and fibrosis at 24 weeks. Results demonstrate concurrent improvements in liver fat content, ALT, liver stiffness, and ELF scores, with 37.8% and 22.7% of patients on 1.2 mg and 1.8 mg doses achieving greater than 0.5 ELF reduction and greater than 30% LSM ...
05-27 12:00
